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PTH revisited. Recent investigations of parathyroid hormone
(PTH) have advanced our understanding of its circulating forms
as well as its action. It is now clear that first-generation immuno-
radiometric assays of so-called intact “PTH” not only measured
full-length PTH(1–84) but also recognized large PTH fragments
lacking the amino-terminus. New, second generation assays de-
tect only full-length PTH. Under diverse pathological settings,
second generation assays display lower levels of PTH (1–84). By
measuring full-length PTH (bioactive PTH) and the combined
full-length plus amino-terminal PTH fragments, the amount of
non-PTH(1–84) in circulation can be estimated. The primary
amino-terminal fragment is likely to be PTH(7–84). A consid-
erable controversy surrounds the pathological significance of
PTH(7–84) and its relation to adynamic bone disease. While
these findings were emerging, other work uncovered the ap-
parent basis by which PTH receptors signal through cAMP in
some instances but through Ca/inositol phosphate in others.
This signaling switch is dictated by the cytoplasmic adapter pro-
tein NHERF1 (EBP50), which is expressed in a cell-selective
fashion. Other provocative findings may provide a means of uni-
fying determinations of PTH(7–84) with the effects of NHERF1
on PTH receptor signaling. These latter studies reveal that in
cells expressing NHERF1, PTH(7–84) has no effect on PTH
receptor signaling or internalization. However, in cells lacking
or expressing low levels of NHERF1, PTH(7–84) internalizes
the PTH receptor without accompanying activation. Together,
these findings suggest that the accumulation of PTH(7–84) in
renal failure may lead to PTH resistance by internalizing and
down-regulating PTH receptors.
Remarkable progress has been achieved in recent years
regarding analysis of parathyroid hormone (PTH) and
understanding its actions on mineral ion homeostasis.
The purpose of this review is to highlight some of these
findings.
PTH is an 84-amino acid peptide that is encoded by
a gene on the short arm of human chromosome 11 and
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chromosome 7 in mice [1]. In addition to encoding the 84
amino acids of the mature peptide, a “pre” sequence of
25 amino acids and a basic “pro” hexapeptide are also en-
coded. This 115–amino-acid translation product is called
preproparathyroid hormone. This single-chain peptide is
rapidly converted to proparathyroid hormone by cleav-
age of 25 amino-terminal residues as the peptide is trans-
ferred to the intracisternal space of the endoplasmic
reticulum. Proparathyroid hormone moves to the Golgi
apparatus, where it is converted to PTH by cleavage of
six amino acids. PTH(1–84) resides within secretory gran-
ules until it is discharged into the circulation. Most of the
PTH normally is degraded by proteolysis before it can
be secreted. A major proteolytic product is PTH(7–84).
This PTH fragment has long been considered inert and a
means for reducing the amount of active, full-length PTH.
A remarkable convergence of new immunoradiometric
assays (IRMA) for PTH, together with recent work on
PTH receptors, suggest that PTH(7–84) and similar, large,
amino-truncated PTH fragments serve important, but as
yet incompletely understood, biologic functions.
It wasn’t appreciated until recently that first generation
immunometric PTH assays measured not only PTH(1–
84) but also shorter, amino-truncated PTH fragments [2].
These first generation assays simplified PTH determina-
tion in renal failure with improved specificity because
the two-site assay was believed to react only with full-
length PTH, and not with the inactive hormone fragments
that accumulate in renal failure [3]. However, because the
detection antibody was directed against epitopes in the
amino terminus, and not at the amino terminus, they rec-
ognized a variety of PTH fragments that lack activity, at
least in terms of simulating adenylyl cyclase, the classic
measure of PTH bioactivity. Unfortunately, the nomen-
clature of these assays is now confusing. These first gen-
eration assays are referred to as measuring intact PTH
because that was believed to be the case. As outlined
above, it is now clear that they measured full-length, as
well as large amino-terminal PTH fragments. The inclu-
sion of PTH fragments was responsible for the fraction of
serum PTH that was not suppressible by calcitriol inter-
vention. Thus, these first generation PTH assays overesti-
mated the serum concentrations of PTH(1–84). Further,
nonsuppressible PTH levels increase prodigiously in
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renal failure and secondary hyperparathyroidism [4, 5],
raising concern that PTH fragments other than intact
PTH were included in these determinations. Further, it
was suggested that the emergence of adynamic bone dis-
ease in these patients was associated with an increased
abundance of non-PTH(1–84) fragments [6]. The pre-
cise molecular identity of these fragments is uncertain;
however, some are indistinguishable from PTH(7–84),
with which they coelute by high-performance liquid chro-
matography (HPLC) [7]. PTH(7–84) and other amino-
truncated PTH fragments accumulate significantly during
renal failure. This occurs for two reasons. First, the frag-
ments are preferentially released under hypercalcemic
conditions, a situation that develops in end-stage renal
failure. Second, these PTH fragments are cleared from
the circulation primarily by the kidneys, whereas intact
PTH is removed by renal and extrarenal mechanisms.
The PTH assay system has been improved by generat-
ing a detection antibody that targets the amino-terminus
of PTH [8]. Second generation assays report PTH as
“whole PTH” [or “cyclase activating PTH (CAP), or
“bioactive PTH”]. These second generation assays can
be used alone or in combination with determination of
“intact PTH,” which reports the sum of PTH(1–84) plus
the large PTH fragments, to give an estimate of PTH(7–
84). The ratio of whole PTH (CAP) to that of PTH(7–84)
[cyclase inactive PTH (CIP)] has been used to predict
the susceptibility for adynamic bone disease and suggest
appropriate therapeutic intervention [9, 10]. The value
of these determinations in predicting adynamic bone dis-
ease, however, has been questioned and is extremely con-
troversial [11–14].
Biologic activity of PTH is generally associated with
the N-terminal portion of the peptide; residues 1 to 27
are required for optimal binding to the PTH receptor
and hormone activity. Derivatives lacking the first or sec-
ond residue bind to PTH receptors, but do not activate
the classic cAMP or Ca2+/inositol phosphate signaling
pathways and are physiologically inert [15]. PTH frag-
ments lacking the first six amino acids, such as PTH(7–34)
or PTH(7–84) are competitive inhibitors of PTH action.
Thus, for instance, PTH(7–84) antagonizes the hypercal-
cemic effects of PTH(1–84) and of PTH(1–34) [5, 16], and
inhibits the action of PTH(1–84) on bone cell number and
turnover [17]. Earlier studies failed to note an effect of
PTH(7–34) analogues on serum calcium in hypercalcemic
mice [18]. These findings suggest that structural elements
in the 36–84 range may be important for the inhibitory ac-
tion of large amino-truncated PTH fragments. Consistent
with such an interpretation, PTH(7–84) and PTH(39–84)
potently inhibit bone resorption blunt and vitamin D–
induced osteoclastogenesis [19]. Notably, these effects
were clearly independent of the type 1 PTH/PTHrP re-
ceptor (PTH1R). The possibility that PTH receptors rec-
ognizing carboxy-terminal PTH fragments (CPTH recep-
tors) (i.e., receptors that responded to amino-truncated
PTH peptides), was suggested some years ago. Amino-
truncated, carboxy PTH fragments such as PTH(53–84)
and PTH(60–84) stimulate alkaline phosphatase activity
and induce expression of mRNAs for both alkaline phos-
phatase and osteocalcin [20, 21]. The strongest evidence
for CPTHRs comes from experiments where PTH(19–
84) binding was demonstrated in osteoblastic and osteo-
cytic cell lines derived from mice in which the PTH1R
gene had been eliminated by gene targeting [22].
Other new findings reveal unexpected effects of
amino-truncated PTH fragments on the PTH1R. The
PTH1R is a member of class B of the superfamily of
G protein–coupled receptors. Other members of this
class include PTH2R, secretin, calcitonin, corticotrophin-
releasing factor, gastric inhibitory peptide, glucagon,
growth hormone-releasing hormone, pituitary adenylate
cyclase activating polypeptide (PACAP), vasoactive in-
testinal polypeptide, and others. Structural features com-
mon to these receptors include the presence of a disul-
fide bridge connecting the second and third extracellu-
lar loop (also present in family A), but they lack the
palmitoylation site found in rhodopsin-like family A re-
ceptors. Other structural distinctions have been noted
[23]. Beyond these structural components, family B re-
ceptors share a functional capacity to activate multiple
second messenger pathways, including adenylyl cyclase
and phospholipase C (PLC). In the case of the PTH recep-
tor, in some cells and heterologous expression systems,
the PTH1R activates both adenylyl cyclase and PLC. In
certain instances, however, the PTH1R couples only to a
single pathway and does so in a cell-specific manner. For
example, in vascular smooth muscle cells, PTH stimulates
adenylyl cyclase, but not PLC [24, 25], whereas in ker-
atinocytes [26–28], cardiac myocytes [29, 30], and lympho-
cytes [31–33], PLC, but not adenylyl cyclase, is activated.
Thus, PTH actions may be mediated by the adenylyl
cyclase → cAMP → protein kinase A (PKA) pathway
and/or PLC → inositol phosphate → protein kinase C
(PKC) route. The recognition that the PTH1R initiates
a broad array of cell-specific signaling patterns empha-
sizes the importance of understanding how such regula-
tion arises, and how it determines renal PTH-dependent
calcium absorption.
In human kidneys, as in most other species, the PTH1R
is expressed in proximal tubules, cortical ascending limbs,
and distal convoluted tubules [34]. Although it has been
generally assumed that PTH receptors are located on
serosal cell membranes, significant evidence now points
to the presence of mucosal membrane PTH1Rs in proxi-
mal tubules [35–37]. The physiologic significance of mu-
cosal PTH receptors has not been elucidated. However, it
is now known that mucosal PTH receptors signal princi-
pally through the PLC/PKC pathway, whereas serosal re-
ceptors are coupled through both adenylyl cyclase/PKA
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and PLC/PKC [36]. Other studies reveal that application
of PTH to either mucosal or serosal surfaces of proxi-
mal tubules internalizes the Na-Pi cotransporter [36] and
inhibits phosphate absorption [37].
Rather remarkable findings may help explain differen-
tial PTH1R signaling by mucosal compared with basolat-
eral PTH receptors. Mahon and Segre [38] recognized
that the intracellular carboxy terminus of the PTH1R
possesses a PDZ recognition motif. These motifs take
their name from their conserved presence in the mam-
malian synaptic protein, PSD-95, Drosophila Dlg, or discs
large, and the adherens junction protein, ZO-1. PDZ do-
mains have been implicated in protein targeting and in
the assembly of protein complexes [39, 40]. Using a yeast
two-hybrid screen of a human kidney cDNA library, Ma-
hon and Segre discovered that the PTH1R bound the
Na/H exchanger regulatory factors NHERF1 (EBP50)
and NHERF2 (E3KARP) [38]. NHERF1 and a related
member of this family NHERF2 are cytoplasmic adap-
tor proteins [41]. Both NHERF1 and NHERF2 con-
tain two tandem PDZ domains (PDZ-I and PDZ-II)
and a C-terminal ezrin-radixin-moesin-merlin (ERM)-
binding region. NHERF1 recruits a variety of cellular
receptors, ion transporters, signaling, and other proteins
to the plasma membrane of transporting epithelia and
other cells [42]. Mahon and Segre identified a role for
NHERF in PTH1R signaling [38]. PTH challenge of
PS120 fibroblasts heterologously expressing the PTH1R
and NHERF2 activated PLC and inhibited adenylyl cy-
clase, whereas in cells expressing the PTH1R, but not
NHERF2, PTH activated adenylyl cyclase without an
effect on PLC. These results provide a potential basis
for explaining the remarkable cell-dependent pattern of
PTH1R signaling, which could not be attributed to differ-
ences in PTH1R abundance, alternatively spliced PTH1R
isoforms, or the pattern or quantity of G proteins. The sig-
naling switch evoked by NHERF, however, seems to be
more complicated than simply depending on the pres-
ence or absence of this cytosolic adapter protein [43].
Possible cooperation between cAMP- and protein kinase
C–dependent pathways, activation or inhibition of unrec-
ognized NHERF-dependent pathways, the involvement
of cis-interacting proteins, the stoichiometry of PTH1R
and NHERF, and NHERF phosphorylation or dimeriza-
tion may also be significant.
Striking cell-specific PTH1R activation attends PTH
action in proximal and distal convoluted tubule cells
(Fig. 1). PTH evokes a prompt, transient increase of
[Ca2+]i in proximal tubule cells, but a delayed and
sustained increase in distal convoluted tubule cells. The
physiologic effects of all G protein–coupled receptors
represent a balance between receptor activation and in-
activation, which is mediated by rapid desensitization
and endocytosis. The finding that PTH1R activation pro-
ceeds in a conspicuous cell-selective manner suggests that
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Fig. 1. Parathyroid hormone (PTH) effects on [Ca2+]i in single proxi-
mal or distal tubule cells. At 2 minutes, 10 nmol/L PTH[1–34] was added
to the bath. Modified from [55].
PTH1R inactivation might also proceed in a cell-specific
fashion. Recent work from our lab supports this theory
and further revealed that it was legislated by NHERF1.
To examine the pattern of PTH1R internalization, we
expressed a human PTH1R tagged with the enhanced
green fluorescent protein (EGFP). Receptor internaliza-
tion was measured by quantitative, live-cell, real-time
monitoring of plasma membrane fluorescence intensity.
Under resting conditions, the receptor is expressed on
serosal plasma membranes of mouse distal and proximal
convoluted tubule cells (the absence of mucosal mem-
brane targeting in proximal cells is intriguing). After
addition of PTH(1–34), the PTH1R was internalized in
both cell types, although with somewhat different kinetics
(Fig. 2A). A number of experimental examples demon-
strate that PTH1R activation and endocytosis can be
dissociated. Each event requires distinct and specific re-
ceptor conformational states. For example, PTH peptide
analogues have been described that efficiently activate
the PTH1R but fail to induce internalization [44]. Con-
versely, PTH1R mutants have been generated that are
phosphorylated by GRK2 and internalize in response
to PTH(1–34), but exhibit limited ability to transduce
G protein–mediated signaling [45]. These observations
raised the possibility that PTH analogues that are un-
able to activate the PTH1R may be capable of induc-
ing receptor endocytosis. We tested this idea by us-
ing PTH(7–34). This synthetic, amino-truncated PTH
analogue binds but does not activate PTH receptors.
PTH(7–34) did not cause PTH1R internalization in
proximal tubule cells (Fig. 2B). However, PTH(7–34)
promptly and efficiently induced receptor sequestra-
tion in distal convoluted tubule cells. PTH1R endo-
cytosis evoked by PTH(7–34) was greater and more
rapid than that elicited by PTH(1–34). Full-length
S-16 Friedman: PTH revisited
0
10
20
30
40
50
60
70
PT
H
1R
 in
te
rn
a
liz
at
io
n,
 %
PCT
DCT
0 3 6 9 12 15
Time after PTH(1-34),
minutes
A
0
20
40
60
80
100
PT
H
1R
 in
te
rn
a
liz
at
io
n,
 %
DCT
PCT
0 3 6 9 12 15
Time after PTH(7-34),
minutes
B
0
20
40
60
80
100
PT
H
1R
 in
te
rn
a
liz
at
io
n,
 %
PTH(7-84)
PTH(1-84)
0 3 6 9 12 15
Time after PTH,
minutes
C Fig. 2. Effects of PTH peptides on PTH1R
internalization in proximal (PCT) and distal
(DCT) kidney tubule cells. (A) PTH(1–34) in-
ternalizes the PTH1R in PCT and DCT cells,
albeit with somewhat different kinetics. (B)
PTH(7–34) avidly promotes PTH1R endocy-
tosis in DCT cells, but has no effect on PCT
cells. (C) Full-length PTH circulating peptides
PTH(1–84) and PTH(7–84) exert effects com-
parable to their shorter synthetic analogues
(i.e., both induce receptor sequestration in
DCT cells).
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Fig. 3. Na/H exchanger regulatory factor (NHERF) expression in-
hibits PTH/PTHrP (PTH1R) endocytosis in distal tubule cells. The
results show the effect of 10−7 mol/L PTH(1–34) or PTH(7–34) on
PTH1R internalization after 15 minutes in the absence or presence of
NHERF1. ∗∗P < 0.01 vs. distal kidney tubule cells (DCT).
PTH(1–84) and PTH(7–84) exert effects similar to their
corresponding shorter synthetic analogues (Fig. 2C).
These findings show that PTH1R activation and inac-
tivation can be dissociated; PTH1R internalization by
PTH(7–34) occurs in a cell-specific manner: PTH1Rs are
internalized by PTH(7–34) in the absence of antecedent
or concomitant activation; and native, circulating forms
of PTH, PTH(1–84), and PTH(7–84) exert comparable
effects.
NHERF1 is expressed by proximal, but not by distal
tubule cells [46]. Because PTH(7–34) had no effect in
proximal cells but promoted PTH1R internalization in
distal tubule cells, we theorized that the presence or ab-
sence of NHERF1, respectively, in these cells accounted
for these findings. To test this hypothesis, NHERF1 was
stably transfected in distal tubule cells. As shown in
Figure 3, the effects of PTH(7–34) were largely blunted
in distal cells expressing NHERF1. The presence of
NHERF1 did not modify PTH(1–34)-induced PTH1R
endocytosis, which remained at approximately 50% at
15 minutes. Because proximal cells abundantly express
NHERF1, we introduced a functional dominant-negative
form of NHERF in these cells as a further test of the
idea that the presence of NHERF defends the PTH1R
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Fig. 4. Dominant-negative Na/H exchanger regulatory factor
(dnNHERF) permits PTH(7–34) to internalize the PTH/PTHrP
(PTH1R) in proximal tubule cells. The effect of 10−7 mol/L PTH(7–34)
on PTH1R internalization is shown after 15-minute stimulation in cells
transiently transfected with dnNHERF1 or empty vector.
from internalization in response to occupancy by PTH(7–
34). The results, illustrated in Figure 4, indicate that in
proximal cells transfected with empty vector, PTH(7–34)
had a negligible effect on PTH1R internalization, as be-
fore. However, the cells harboring dominant-negative
NHERF1 (dnNHERF1) exhibited a robust internaliza-
tion that averaged 60% after a 15-minute exposure. This
finding indicates that interfering with the ability of the
PTH1R to interact with NHERF1 confers internalization
behavior on PTH(7–34), such as in distal tubule cells that
normally lack NHERF1.
The PTH1R PDZ-recognition sequence is ETVM, cor-
responding to a canonic PDZ domain of D/E-S/T-X-
, where X is any amino acid and  is a hydrophobic
residue, generally L/I/V, but can also be M [47]. The pi-
oneering work of Mahon and Segre showed that intra-
cellular PTH1R tail proteins bound NHERF2. We ex-
tended these observations to the full-length PTH1R. This
was demonstrated in human embryonic kidney (HEK)-
293 cells coexpressing EGFP-tagged wild-type PTH1R
with HA-tagged NHERF1. HEK-293 cells were used
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Fig. 5. Coimmunoprecipitation of Na/H exchanger regulatory factor
(NHERF1) with PTH1R(ETVM)-EGFP and PTH1R(ETVA)-EGFP.
Human embryonic kidney (HEK)-293 cells transfected with the indi-
cated constructs. Immunoprecipitation experiments were performed
by incubating the cell lysates with an EGFP-specific polyclonal anti-
body. Immunoblotting was performed with an HA-specific monoclonal
antibody (upper panel). The amount of immunoprecipitated EGFP-
tagged receptor in each sample was verified by immunoblotting with
the EGFP-specific polyclonal antibody (middle panel). The quantity
of HA-NHERF1 present in each cell extract was evaluated by im-
munoblotting with the HA-specific monoclonal antibody (lower panel).
Modified from [48]. See text for abbreviations.
because they are normally devoid of PTH1R. Cell lysates
were immunoprecipitated with a GFP-specific polyclonal
antibody, and blotting was performed with an HA-
specific monoclonal antibody. As shown in Figure 5 (top),
NHERF1 efficiently coimmunoprecipitated with the
PTH1R. This finding also established that such interac-
tion occurs constitutively (i.e., without ligand occupancy).
Mutation of any residue of the PDZ sequence of the
PTH1R, other than the permissive position, abrogates in-
teraction with NHERF1 or NHERF2 [38]. We generated
a full-length PTH1R/EGFP construct, wherein the termi-
nal methionine was changed to alanine (M593A). In con-
trast to the wild-type ETVM-PTH1R, the ETVA-PTH1R
did not coimmunoprecipitate with EBP50 (Fig. 5, top).
Immunoblotting of the cell lysates with an anti-GFP an-
tibody showed that both wild-type and ETVA-PTH1R
were expressed at similar levels (Fig. 5, middle). Like-
wise, immunoblotting of the cell lysates with the HA-
specific antibody showed that EBP50 expression levels
were similar in all conditions (Fig. 5, bottom). Thus, mu-
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Fig. 6. Na/H exchanger regulatory factor (NHERF1) effects on
parathyroid hormone (PTH)-induced internalization in distal tubule
cells expressing either the wild-type PTH/PTHrP (PTH1R) PDZ-
recognition motif or the mutated ETVA PDZ-binding domain. The
results depict the effect of 10−7 mol/L PTH(1–34) or PTH(7–34) for 15
minutes. ∗∗P < 0.01 vs. wild-type PTH1R. See text for abbreviations.
tation of a single residue of the PDZ-recognition domain
was sufficient to disrupt the association of the PTH1R
with EBP50. These results, along with others not de-
scribed here, demonstrate that the presence of EGFP at
the carboxy-terminus of the PTH1R does not occlude or
interfere with the PDZ-recognition domain, binding to
EBP50, or PTH1R signaling [48, 49].
The ETVA-PTH1R allowed us to examine further
the argument that an intact PDZ-binding domain was
necessary and sufficient for mediating PTH1R interac-
tions with NHERF1. We predicted that if the ETVA-
PTH1R did not bind the PTH1R, as shown in Figure 5,
then it should be ineffective in defending the PTH1R
against internalization. This postulate was tested by com-
paring the effects of NHERF1 when introduced into dis-
tal tubule cells harboring the wild-type ETVM PTH1R
PDZ-binding domain or the mutated ETVA-PTH1R. As
shown in Figure 6, the ETVA-PTH1R was equally well in-
ternalized in response to PTH(1–34), as was the wild-type
PTH1R. However, whereas NHERF1 curtailed PTH1R
endocytosis in response to PTH(7–34), it exerted no de-
tectable inhibitory action on the ETVA-PTH1R. These
results establish that an intact PDZ-recognition motif is
necessary and sufficient to mediate the physical interac-
tion with the PTH1R.
As noted earlier, NHERFs contain two tandem PDZ
domains and an ERM domain, which binds to actin-
associated proteins, ezrin, radixin, moesin (ERM), and
merlin [50], and tethers the complex to cytoskeletal
elements in a phosphorylation-dependent manner, and
to the catalytic and regulatory subunits of protein ki-
nase A [39]. Additional studies extended the analysis of
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PTH1R-NHERF-actin interaction by examining the ef-
fect of a truncated form of NHERF1 lacking the ERM
domain and of actin-disrupting agents on PTH1R inter-
nalization. Consistent with the view that all elements
are required for a coherent defense against PTH(7–34)-
induced receptor internalization, we found that ERM-
deficient NHERF1 failed to prevent PTH1R internaliza-
tion in response to PTH(7–34). Further, cytochalasin D,
an inhibitor of actin polymerization, permitted PTH(7–
34) to promote receptor internalization. Thus, degrada-
tion of any component of this system, the PTH1R PDZ-
binding domain, NHERF1, or the actin cytoskeleton, al-
lows PTH(7–34) to internalize the PTH1R.
CONCLUSION
These findings raise a host of intriguing questions. How,
for instance, is the PTH1R targeted for internalization if
it has not been activated? If the PTH1R is not stimu-
lated by PTH(7–34), does this indicate that b-arrestins
are not involved in endocytosis? What is the fate of a re-
ceptor that is internalized without having been activated?
The answers to these questions may help understand the
fate of the PTH1R in renal failure, and provide a basis
to integrate many of the new findings summarized here.
Selective PTH resistance accompanies renal failure and
secondary hyperparathyroidism. In this setting, PTH(7–
84) accumulates to high levels as a consequence of prefer-
ential release and diminished peripheral metabolism [2,
9, 11, 51]. PTH resistance in end-stage renal failure has
been suggested to result from competitive inhibition of in-
tact PTH by these amino-terminally truncated PTH frag-
ments [5]. However, PTH1R down-regulation has been
described in the same pathologic setting [52, 53], and this
would be inconsistent with PTH(7–84) antagonism of
receptor endocytosis and degradation. Based on the
findings described here, we advance an alternative
mechanism for PTH resistance. According to this view,
in selected hormone target tissues, such as the distal
nephron, PTH(7–84) contributes to hormone resistance
by internalizing and down-regulating the PTH1R with-
out accompanying activation. Reducing the numbers of
plasma membrane–delimited PTH receptors diminishes
the action of full-length or amino-terminal PTH frag-
ments on calcium absorption that is mediated by this
nephron segment. PTH(1–84), we imagine, continues
to inhibit proximal tubule phosphate transport because
PTH(7–84) does not internalize the PTH1R in proximal
tubule cells. This reduced effect of PTH on the distal
nephron may represent a protective action to avoid con-
comitant hypercalcemia in the face of frank hyperphos-
phatemia. If comparable integrative effects occur in the
intact organism they would permit continued proximal
tubule phosphate excretion that is not accompanied by
distal nephron calcium reabsorption. This, in turn, would
limit the rise of the Ca × P product, which is recognized as
an important risk for vascular calcification and mortality
[54].
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